Hanmi Holdings

Hanmi Science is the holding company for the Hanmi Pharmaceutical Group, a prominent South Korean biopharmaceutical organization dedicated to the development of innovative therapies. The company is best known for its proprietary LAPSCOVERY (Long Acting Protein/Peptide Discovery) platform, which significantly extends the half-life of biologic drugs to improve patient compliance and efficacy. Its diverse pipeline focuses on metabolic diseases, oncology, and rare diseases, featuring high-profile assets like efinopegdutide and efpeglenatide. Hanmi Science oversees a vertically integrated structure including R&D, manufacturing, and distribution subsidiaries. Through strategic global partnerships with major pharmaceutical firms, the company has established itself as a leader in the Korean biotech sector's transition toward original drug innovation.